In Vitro Methotrexate as a Practical Approach to Selective Allodepletion

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 6, 2007, Pages 644-654

  Sathe, Atul ^a   Ortega, Sterling B ^a   Mundy, Dorothy I ^a   Collins, Robert H ^a   Karandikar, Nitin J ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Allodepletion; GVHD

Indexed keywords

ANTIMETABOLITE; CD4 ANTIGEN; CD8 ANTIGEN; HLA ANTIGEN; METHOTREXATE; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DONOR; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MORBIDITY; MORTALITY; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RECIPIENT; T CELL DEPLETION; T LYMPHOCYTE; VIRUS IMMUNITY;

ANTIGENS, VIRAL; CELL PROLIFERATION; CELLS, CULTURED; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY TESTING; HUMANS; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTE DEPLETION; METHODS; METHOTREXATE; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 34248634627     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.01.081     Document Type: Article

References (43)

1. Appelbaum F.R. The current status of hematopoietic cell transplantation. Annu Rev Med 54 (2003) 491-512
2. Ferrara J.L.M., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
3. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75 (1990) 1024-1030
4. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 354 (2006) 1813-1826
5. Couriel D., Caldera H., Champlin R., and Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 101 (2004) 1936-1946
6. Rieger K., Loddenkemper C., Maul J., et al. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GVHD. Blood 107 (2006) 1717-1723
7. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104 (2004) 2187-2193
8. Jones S.C., Murphy G.F., and Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant 9 (2003) 243-256
9. Ferrara J.L., Cooke K.R., and Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol 78 (2003) 181-187
10. Ferrara J.L.M., Levy R., and Chao N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5 (1999) 347-356
11. Kernan N.A., Bordignon C., Heller G., et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 74 (1989) 2227-2236
12. Delain M., Cahn J.Y., Racadot E., et al. Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients. Leuk Lymphoma 11 (1993) 359-368
13. Keever C.A., Small T.N., Flomenberg N., et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts. Blood 73 (1989) 1340-1350
14. Roux E., Helg C., Dumont-Girard F., Chapuis B., Jeannet M., and Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87 (1996) 3984-3992
15. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
16. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
17. Michalek J., Collins R.H., Durrani H.P., et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A 100 (2003) 1180-1184
18. Datta A.R., Barrett A.J., Jiang Y.Z., et al. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 14 (1994) 517-524
19. Godfrey W.R., Krampf M.R., Taylor P.A., and Blazar B.R. Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. Blood 103 (2004) 1158-1165
20. Wehler T.C., Nonn M., Brandt B., et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 109 (2007) 365-373
21. Le N.T., Chen B.J., and Chao N.J. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting. Cytotherapy 7 (2005) 126-133
22. Martins S.L., St John L.S., Champlin R.E., et al. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood 104 (2004) 3429-3436
23. Garderet L., Snell V., Przepiorka D., et al. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. Transplantation 67 (1999) 124-130
24. Davies J.K., Koh M.B., and Lowdell M.W. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biol Blood Marrow Transplant 10 (2004) 259-268
25. Montagna D., Yvon E., Calcaterra V., et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 93 (1999) 3550-3557
26. Amrolia P.J., Muccioli-Casadei G., Yvon E., et al. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood 102 (2003) 2292-2299
27. Hartwig U.F., Nonn M., Khan S., Meyer R.G., Huber C., and Herr W. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 37 (2006) 297-305
28. Fehse B., Goldmann M., Frerk O., Bulduk M., and Zander A.R. Depletion of alloreactive donor T cells using immunomagnetic cell selection. Bone Marrow Transplant 25 Suppl 2 (2000) S39-S42
29. Fehse B., Frerk O., Goldmann M., Bulduk M., and Zander A.R. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol 109 (2000) 644-651
30. Szabolcs P., Park K.D., Marti L., et al. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin. Biol Blood Marrow Transplant 10 (2004) 772-783
31. Genestier L., Paillot R., Quemeneur L., Izeradjene K., and Revillard J.-P. Mechanisms of action of methotrexate. Immunopharmacology 47 (2000) 247-257
32. Kremer J.M. Methotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29 (1999) 14-26
33. Karandikar N.J., Crawford M.P., Yan X., et al. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J Clin Invest 109 (2002) 641-649
34. Crawford M.P., Yan S.X., Ortega S.B., et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 103 (2004) 4222-4231
35. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 243 (2000) 147-154
36. Genestier L., Paillot R., Fournel S., Ferraro C., Miossec P., and Revillard J.-P. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102 (1998) 322-328
37. Paillot R., Genestier L., Fournel S., Ferraro C., Miossec P., and Revillard J.P. Activation-dependent lymphocyte apoptosis induced by methotrexate. Transplant Proc 30 (1998) 2348-2350
38. Cronstein B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57 (2005) 163-172
39. Swierkot J., Miedzybrodzki R., Szymaniec S., and Szechinski J. Activation dependent apoptosis of peripheral blood mononuclear cells from patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 63 (2004) 599-600
40. Scheinberg P., Price D.A., Ambrozak D.R., Barrett A.J., and Douek D.C. Alloreactive T cell clonotype recruitment in a mixed lymphocyte reaction: implications for graft engineering. Exp Hematol 34 (2006) 788-795
41. Strauss G., Osen W., and Debatin K.M. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128 (2002) 255-266
42. Hoffmann P., Ermann J., Edinger M., Fathman C.G., and Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 196 (2002) 389-399
43. Taylor P.A., Lees C.J., and Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99 (2002) 3493-3499